ClinicalTrials.gg
TerminatedNCT03276728Updated Aug 8, 2022Results posted

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

A Phase 1 interventional study of AMG 986 IV and AMG 986 PO in Heart Failure and Healthy Volunteer, sponsored by Amgen. Terminated at 25 sites in 9 countries. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-08.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Terminated (Decision by the Sponsor. The study was not terminated due to a safety reason.)

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2016, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Heart Failure by Amgen — 1 open to participants now, 1 under way, 1 of them phase 3. Heart Failure · Amgen.

Started
2016
the only one that year
Phase 1
2 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Heart Failure by Amgen, this one is the only one that started in 2016, is one of 2 in phase 1, and was the 7th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 11 studies in Heart Failure by Amgen is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by Amgen, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).

Read the detailed description

This study is a randomized, placebo-controlled, double-blind, single day ascending dose (SDAD) study (Part A), a multiple daily ascending dose (MDAD) study (Part B), in healthy adults, and a MDAD study (Part C) in heart failure patients. In Parts A and B of the study, healthy volunteers will receive AMG 986 by continuous IV infusion or by oral administration in a fasted state. IV Infusions will be divided into an initial loading dose (LD) for the first hour followed immediately by a maintenance dose (MD).

In Part C of the study, patients with heart failure and either reduced (HFrEF) or preserved (HFpEF) ejection fraction will receive MDAD of AMG 986 or matching placebo once daily by oral administration for 21 days.

03

Conditions studied

  • Heart Failure
  • Healthy Volunteer

Keywords

  • Heart Failure
  • Cardiovascular Diseases
  • Heart Diseases
  • Ejection fraction
  • Heart Failure with reduced ejection fraction
  • Heart Failure with preserved ejection fraction
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study-specific activities/procedures.
  • Male and female subjects ≥ 18 to ≤ 55 years old with no history or evidence of medical disorders as determined by the investigator and the Amgen physician (Parts A and B only)
  • (BMI) between 18 and 35 kg/m\^2, inclusive, at screening.
  • Physical examination including vital signs, clinical laboratory values, and (ECGs) are clinically acceptable to the investigator. Abnormal findings for healthy volunteers and unexpected findings for heart failure patient subjects will be discussed with Amgen prior to study enrollment.
  • Women must be of non- (ie, )
  • Men must agree to practice an acceptable method of effective while on study through 11 weeks after receiving the last dose of product (AMG 986 or placebo). Acceptable methods of effective birth control include sexual abstinence; vasectomy and testing that shows there are no sperm in the semen; or a condom with spermicide (men) in combination with barrier methods (diaphragm, cervical cap or cervical sponge), hormonal birth control or IUS (women).
  • Men must be willing to abstain from sperm donation while on study through 11 weeks after receiving the last dose of investigational product (AMG 986 or placebo).
  • This inclusion criterion only applies to Parts B and C cohorts. Before inclusion in the study, subjects will undergo a screening echocardiogram to ensure that the following parameters can be accurately measured: left ventricular end-systolic and end-diastolic volumes, left atrial end-systolic and end-diastolic volumes, , fraction shortening, and end-systolic septal and posterior wall thickness.

For Part C

Additional Inclusion Criteria for HFrEF Patients:

  • Subject must be of age 18 to 85 years, have a diagnosis of HF confirmed by medical records for ≥ 3 months, and be in stable condition for at least 4 weeks.
  • Left ventricular ejection fraction (LVEF) ≤ 40% confirmed by echocardiogram, radionuclide ventriculography, cardiac magnetic resonance imaging, or contrast ventriculography within 12 months prior to randomization.
  • (NYHA) class II or III at screening
  • Sinus rhythm
  • N-terminal pro b-type natriuretic peptide (NT-proBNP) level ≥ 250 pg/ml
  • Patients will be treated with stable, optimal pharmacological therapy for a minimum of 4 weeks prior to randomization. Treatment of HFrEF includes at least beta-blockers (carvedilol, metoprolol succinate or bisoprolol) and a RAAS inhibitor (ACEi, ARB or sacubitril/valsartan).

Additional Inclusion Criteria for HFpEF patients:

  • Subject must be of age of 18 to 85 years, have a diagnosis of HF confirmed by medical records for ≥ 3 months, and be in stable condition for at least 4 weeks.
  • LVEF ≥ 50% confirmed by echocardiogram, radionuclide ventriculography, cardiac magnetic resonance imaging, or contrast ventriculography within 12 months prior to randomization.
  • LVEF never ≤ 40% in the past
  • NYHA class II or III at screening
  • Sinus rhythm
  • NT-proBNP level ≥ 250 pg/ml
  • Patients will be treated with stable, optimal pharmacological therapy for a minimum of 4 weeks prior to randomization. Treatment of HFpEF includes at least a daily dose of diuretics equivalent to furosemide 40 mg.
  • For subjects in Parts A, B and C: Women must have negative results for both the screening (serum) and day -1 (serum or urine) pregnancy tests

Exclusion criteria

Exclusion Criteria

  • Currently receiving treatment in another device or drug study, or less than 30 days or 5 half-lives (whichever is longer), since ending treatment on another investigational device or drug study(s) prior to receiving the first dose of investigational product (AMG 986 or placebo).
  • Female subjects who are lactating/breastfeeding or who plan to breastfeed while on study through 11 weeks after receiving the last dose of investigational product (AMG 986 or placebo).
  • Male subjects with partners who are pregnant or planning to become pregnant while the subject is on study through 11 weeks after receiving the last dose of investigational product (AMG 986 or placebo).
  • Female subjects of .
  • Subjects in Parts A and B of the study: estimated (eGFR) within the screening period of less than 60 mL/min/1.73m\^2 as calculated using the estimated Modification of Diet in Renal Disease (MDRD) formula.
  • Current or prior within 5 years of randomization, with the exception of non-melanoma skin cancers, cervical or breast ductal carcinoma in situ, and adenocarcinoma of the prostate Stage I or IIa (defined as T1, T2a or T2b, N0, M0 with documented serum prostate-specific antigen (PSA) \< 20 ng/mL and Gleason score ≤ 7) per the American Joint Committee on Cancer (AJCC) primary tumor, regional lymph nodes, and distant system.
  • Positive results for (HIV), antibodies, surface antigen (HBsAg), or antibodies (HepCAb).
  • Subject has known sensitivity to any of the products or components to be administered during dosing.
  • Subject likely to not be available to complete all protocol required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge.
  • History or evidence of any other disorder, condition or disease with the exception of those outlined above that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Subject previously has entered this study or has been previously exposed to AMG 986.
  • Concurrent or prior use of strong inhibitors within 14 days of study Day 1, including (not limited to): macrolide antibiotics (eg, clarithromycin, telithromycin), antifungals (eg, itraconazole, voriconazole), antivirals (eg, ritonavir, saquinavir, indinavir, nelfinavir), nefazodone.
  • Concurrent or prior ingestion of grapefruit or grapefruit products and other foods that are known to inhibit CYP3A4 within 7 days of study Day 1.
  • Concurrent or prior use of strong CYP3A4 inducers within 28 days of study Day 1, Including (not limited to): phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital. Subjects should also not take St John's Wort.
  • Concurrent or prior use of strong P-glycoprotein inhibitors within 28 days of study Day 1, including (not limited to): elacridar and valspodar.
  • All herbal supplements, vitamins, and nutritional supplements taken within the last 30 days prior to dosing on Day 1 (and continued use, if appropriate), must be reviewed and approved by the PI and Amgen Medical Monitor.
  • For subjects enrolled under Amendments 1-6, inclusive: > 450 msec or history/evidence of long QT syndrome.
  • Planned elective surgery within 30 days of study completion or before return of red blood cell parameters to normal values.
  • Blood donation ≥ 500 mL within 60 days of Day 1.
  • Systolic blood pressure > 150 mmHg or \< 90 mmHg, or diastolic blood pressure > 95 mmHg or \< 60 mmHg, assessed on 2 separate occasions prior to enrollment (Parts A and B only).
  • Heart rate ≥ 100 beats per minute after 5 minutes of rest or an untreated symptomatic bradyarrhythmia within 1 month prior to enrollment.
  • For Parts A and B: Troponin I at screening > (ULN).
  • In the opinion of the Investigator, a condition that compromises the ability of the subject to give written or to comply with study procedures.
  • Unwilling or unable to abstain from nicotine or tobacco containing products (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, pipes, or nicotine patches) throughout the screening period and for the duration of the study.
  • Subjects who are unwilling or unable to limit alcohol consumption to 1 units/day (1 unit = 1 drink and 1 drink is equivalent to 12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of wine or 1.5 ounces of 80 proof distilled spirits).
  • Subjects with a positive urine drug screen or alcohol breath test.
  • Known history of drug or alcohol abuse.
  • Concurrent use of phosphodiesterase 5 (PDE5) inhibitors including (not limited to) avanafil, sildenafil, tadalafil, vardenafil.
  • Concurrent use of vasodilators by healthy subjects in Parts A and B that could in the opinion of the investigator potentially lead to a drop in blood pressure in combination with investigational product.
  • Severe uncorrected valvular heart disease, or hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease.
  • For subjects in Part C of the study: eGFR within the screening period of less than 30 mL/min/1.732m\^2 as calculated using the MDRD formula.
  • For subjects in Part C of the study: Systolic blood pressure > 160 mmHg or \< 100 mmHg, or diastolic blood pressure > 110 mmHg or \< 60 mmHg, assessed on 2 separate occasions prior to enrollment.
  • For subjects in Part C of the study: troponin I > ULN if there is also evidence of an acute cardiovascular event.
  • For subjects enrolled in Part C under Amendment 7: QTc > 500 msec or history/evidence of long QT syndrome.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
182 participants (actual)

Study arms

  • Placebo comparator
    Part A: Placebo

    Healthy participants were administered placebo either intravenously (IV) or by mouth (PO) to match the 5 IV cohorts and 6 PO cohorts of AMG 986.

    Drug: Placebo PO · Drug: Placebo IV

  • Experimental
    Part A: AMG 986

    Healthy participants were administered a single dose of AMG 986 either IV or PO. The 5 IV cohorts started at a 0.5 mg loading dose over one hour up to to the Cohort 5 IV dosage consisting of a 60 mg loading dose over 1 hour and a 360 mg maintenance dose lasting 23 hours. The 6 PO cohorts started at a single 5 mg dose up to the Cohort 6 PO dose of 650 mg.

    Drug: AMG 986 IV · Drug: AMG 986 PO

  • Placebo comparator
    Part B: Placebo

    Healthy participants were administered placebo either IV for 4 consecutive days or PO for 7 days to match the 2 IV cohorts and 6 PO cohorts of AMG 986.

    Drug: Placebo PO · Drug: Placebo IV

  • Experimental
    Part B: AMG 986

    Healthy participants were administered AMG 986 either IV or PO. IV cohort 1 was administered a loading dose of 6 mg over one hour followed by maintenance doses of 36 mg lasting 23 hours on Day 1 and 38 mg lasting 24 hours on Days 2-4. IV cohort 2 was administered a loading dose of 60 mg over one hour followed by maintenance doses of 360 mg lasting 23 hours on Day 1 and 376 mg lasting 24 hours on Days 2-4. The 6 PO cohorts started at 5 mg for 7 days up to Cohort 6 PO dose of 650 mg for 7 days.

    Drug: AMG 986 IV · Drug: AMG 986 PO

  • Placebo comparator
    Part C: HFrEF Placebo

    Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO placebo tablet daily from Days 1-21.

    Drug: Placebo PO

  • Placebo comparator
    Part C: HFpEF Placebo

    Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO placebo tablet daily from Days 1-21.

    Drug: Placebo PO

  • Experimental
    Part C: HFrEF AMG 986

    Participants with heart failure with reduced ejection fraction (HFrEF) were administered a single PO AMG 986 tablet daily from Days 1-21 in ascending doses of 10 mg for Days 1-7, 30 mg for Days 8-14 and 100 mg for days 15-21.

    Drug: AMG 986 PO

  • Experimental
    Part C: HFpEF AMG 986

    Participants with heart failure with preserved ejection fraction (HFpEF) were administered a single PO AMG 986 tablet daily from Days 1-21 in ascending doses of 10 mg for Days 1-7, 30 mg for Days 8-14 and 100 mg for days 15-21.

    Drug: AMG 986 PO

Interventions

  • DrugAMG 986 IV

    AMG 986 solution for infusion

  • DrugAMG 986 PO

    AMG 986 tablets for oral (PO) administration

  • DrugPlacebo PO

    Matching placebo tablets for oral administration

  • DrugPlacebo IV

    Matching placebo solution for infusion

06

What researchers measure

Primary outcomes

  1. Participants With Treatment Emergent Adverse Events (TEAE)

    An adverse event is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. Events categorized as TEAEs started on or after first dose of study drug and include up to 30 days after the last dose. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.

    Time frame: Part A: Day 1 up to Day 31 Part B: Day 1 up to Day 37 Part C: Day 1 up to Day 51

Secondary outcomes

  1. Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort

    Heart failure (HF) refers to a clinical condition in which the cardiac output is insufficient to meet the metabolic needs of body organs and is marked by cardiac systolic and/or diastolic dysfunction. Heart failure with predominantly systolic dysfunction, which is identifiable as decreased contraction, is more aptly described as heart failure with reduced ejection fraction (HFrEF). Ejection fraction is a measurement, expressed as a percentage, of how much blood the left ventricle pumps out with each contraction and is measured by echocardiogram.

    Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30

  2. Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort

    Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction reported by volumetric method of disks (MoD) assessment.

    Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30

  3. Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort

    Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction as measured using left ventricular outflow tract (LVOT) Doppler assessment.

    Time frame: Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30

07

Results

Posted Aug 8, 2022
Limitations and caveats
This study was terminated early because the clinical development program was terminated. Therefore, no formal PK or pharmacodynamic analyses were conducted.

Participant flow

Participants were enrolled at 13 study centers in 7 countries (Canada, France, New Zealand, Netherland, Poland, Singapore, United States). The study included Parts A, B (healthy volunteers) and C (participants with either heart failure with reduced ejection fraction \[HFrEF\] or heart failure with preserved ejection fraction \[HFpEF\]). Each part of the study consisted of ascending dose cohorts.

Participant flow — Overall Study
MilestonePart A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986
Started2266165071173
Treated participants2266165071163
Completed2266144561152
Not completed00251021
Withdrew: Lost to follow-up00220000
Withdrew: Withdrawal by subject00030000
Withdrew: Decision by sponsor00001021

Outcome measures

PrimaryParticipants With Treatment Emergent Adverse Events (TEAE)

An adverse event is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. Events categorized as TEAEs started on or after first dose of study drug and include up to 30 days after the last dose. A serious AE is an AE that met one or more of the following criteria: * Death * Life-threatening * Required inpatient hospitalization or prolongation of an existing hospitalization * Resulted in persistent or significant disability/incapacity * A congenital anomaly/birth defect * Important medical events that required medical or surgical intervention to prevent one of the outcomes above.

Time frame:
Part A: Day 1 up to Day 31 Part B: Day 1 up to Day 37 Part C: Day 1 up to Day 51
Reported as:
Count of participants · Participants
Participants With Treatment Emergent Adverse Events (TEAE)
ParticipantsPart A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986
All treatment-emergent adverse events (TEAEs)311272163
Serious adverse events00000001
TEAEs leading to discontinuation of study drug00000012
Fatal adverse events00000000
SecondaryLeft Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort

Heart failure (HF) refers to a clinical condition in which the cardiac output is insufficient to meet the metabolic needs of body organs and is marked by cardiac systolic and/or diastolic dysfunction. Heart failure with predominantly systolic dysfunction, which is identifiable as decreased contraction, is more aptly described as heart failure with reduced ejection fraction (HFrEF). Ejection fraction is a measurement, expressed as a percentage, of how much blood the left ventricle pumps out with each contraction and is measured by echocardiogram.

Time frame:
Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Reported as:
Mean · percent of total left ventricular blood
Left Ventricular Ejection Fraction by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
percent of total left ventricular bloodPart C: HFrEF PlaceboPart C: HFrEF AMG 986
Baseline33.300 ± 8.42028.380 ± 6.483
Day 834.900 ± 12.44132.553 ± 7.055
Day 1533.533 ± 9.19431.614 ± 7.154
Day 2133.550 ± 8.89631.436 ± 5.953
Day 3033.171 ± 8.14031.987 ± 7.036
SecondaryStroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort

Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction reported by volumetric method of disks (MoD) assessment.

Time frame:
Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Reported as:
Mean · mL
Stroke Volume (Method of Disks, Volumetric Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
mLPart C: HFrEF PlaceboPart C: HFrEF AMG 986
Baseline53.387 ± 16.99540.461 ± 14.193
Day 855.185 ± 19.15846.130 ± 13.927
Day 1552.673 ± 19.51446.784 ± 14.348
Day 2154.113 ± 18.78944.014 ± 12.051
Day 3053.621 ± 19.25844.634 ± 13.491
SecondaryStroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort

Stroke volume is the amount of blood pumped by the left ventricle of the heart in one contraction as measured using left ventricular outflow tract (LVOT) Doppler assessment.

Time frame:
Baseline (Day 1 predose), Day 8, Day 15, Day 21, Day 30
Reported as:
Mean · mL
Stroke Volume (Left Ventricular Outflow Tract Using Doppler Assessment) by Visit for Part C Heart Failure With Reduced Ejection Fraction (HFrEF) Cohort
mLPart C: HFrEF PlaceboPart C: HFrEF AMG 986
Baseline59.056 ± 18.12054.739 ± 14.523
Day 852.657 ± 13.23153.512 ± 14.943
Day 1553.985 ± 21.58053.073 ± 14.747
Day 2155.805 ± 26.12753.858 ± 14.339
Day 3055.113 ± 20.90050.616 ± 14.212

Adverse events

Collected over Part A: Day 1 up to Day 31 Part B: Day 1 up to Day 37 Part C: Day 1 up to Day 51. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo Pooled0/22 (0%)0/22 (0%)3/22 (13.6%)
Part A: AMG 986 Pooled0/66 (0%)0/66 (0%)8/66 (12.1%)
Part B: Placebo Pooled0/16 (0%)0/16 (0%)2/16 (12.5%)
Part B: AMG 986 Pooled0/50 (0%)0/50 (0%)7/50 (14%)
Part C: HFrEF Placebo0/7 (0%)0/7 (0%)2/7 (28.6%)
Part C: HFpEF Placebo0/1 (0%)0/1 (0%)1/1 (100%)
Part C: HFrEF AMG 9860/17 (0%)0/16 (0%)6/16 (37.5%)
Part C: HFpEF AMG 9860/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventPart A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986
Pleuritic painRespiratory, thoracic and mediastinal disorders0/220/660/160/500/70/10/161/3
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPart A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986
DizzinessNervous system disorders0/220/660/160/500/71/12/161/3
NauseaGastrointestinal disorders0/221/660/161/500/70/11/161/3
Oral mucosal eruptionGastrointestinal disorders0/220/660/160/500/70/10/161/3
AstheniaGeneral disorders0/220/660/160/500/70/10/161/3
Upper respiratory tract infectionInfections and infestations0/220/661/160/500/70/10/161/3
HypoglycaemiaMetabolism and nutrition disorders0/220/660/160/500/70/10/161/3
HypokalaemiaMetabolism and nutrition disorders0/220/660/160/500/70/10/161/3
HypomagnesaemiaMetabolism and nutrition disorders0/220/660/160/500/70/10/161/3
HypotensionVascular disorders0/220/660/160/500/70/10/161/3
Swelling of eyelidEye disorders0/220/660/160/501/70/10/160/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986Total
Mean37.2 ± 9.439.5 ± 9.836.9 ± 10.037.4 ± 9.861.6 ± 10.173.064.3 ± 7.869.0 ± 1.042.3 ± 13.4
Age, Customized
Age, Customized(Participants)Part A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986Total
18-64 years2266165040110169
65-84 years0000316313
85 years and over000000000
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986Total
Female0701313217
Male2259164940141165
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986Total
Hispanic or Latino62215100035
Not Hispanic or Latino1644154561172146
Unknown or Not Reported000000011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Placebo PooledPart A: AMG 986 PooledPart B: Placebo PooledPart B: AMG 986 PooledPart C: HFrEF PlaceboPart C: HFpEF PlaceboPart C: HFrEF AMG 986Part C: HFpEF AMG 986Total
Asian36611202030
Black516517207254
Native Hawaiian or Other Pacific Islander000100001
White1135518318081
Other1803000113
Multiple210000003
08

Study locations

25 sites
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Minneapolis, Minnesota 55415, United States
  • Research Site
    Las Vegas, Nevada 89148, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Auchenflower, Queensland 4066, Australia
  • Research Site
    Bundaberg, Queensland 4670, Australia
  • Research Site
    Leabrook, South Australia 5068, Australia
  • Research Site
    Berwick, Victoria 3806, Australia
  • Research Site
    Bundoora, Victoria 3083, Australia
  • Research Site
    Sherbrooke, Quebec J1G 2E8, Canada
  • Research Site
    Nantes Cedex 1, 44093, France
  • Research Site
    Paris, 75015, France
  • Research Site
    Rennes Cedex 9, 35033, France
  • Research Site
    Toulouse Cedex 9, 31059, France
  • Research Site
    Bad Neuheim, 61231, Germany
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Christchurch, 8011, New Zealand
  • Research Site
    Jozefow, 05-410, Poland
  • Research Site
    Wroclaw, 51-162, Poland
  • Research Site
    Singapore, 169609, Singapore
09

References and documents

Publications

  • Winkle P, Goldsmith S, Koren MJ, Lepage S, Hellawell J, Trivedi A, Tsirtsonis K, Abbasi SA, Kaufman A, Troughton R, Voors A, Hulot JS, Donal E, Kazemi N, Neutel J. A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients. Cardiovasc Drugs Ther. 2023 Aug;37(4):743-755. doi: 10.1007/s10557-022-07328-w. Epub 2022 Apr 23. PubMed 35460392 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Apr 2019, 32 months.

Results were first posted in Aug 2022, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2017
First posted
Sep 8, 2017
StartActual
Aug 12, 2016
Primary completionActual
Apr 18, 2019
CompletionActual
Apr 18, 2019
Results first posted
Aug 8, 2022
Last update
Aug 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03276728
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 8, 2017
Start date
Aug 12, 2016
Primary completion
Apr 18, 2019
Completion
Apr 18, 2019
Results posted
Aug 8, 2022
Last update
Aug 8, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion